1,189 results on '"Fujihara, Kazuo"'
Search Results
2. Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis
3. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
4. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
5. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
6. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
7. White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease
8. Neuromyelitis optica spectrum disorders registry system in Iran: Validity of data sets
9. Stochastic models for the onset and disease course of multiple sclerosis
10. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database
11. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
12. Dynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: A Japanese nationwide administrative data study
13. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study
14. Artificial intelligence extension of the OSCAR‐IB criteria
15. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker
16. Associations between neuromyelitis optica spectrum disorder, Sjögren's syndrome, and conditions with electrolyte disturbances
17. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach
18. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
19. A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
20. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria
21. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
22. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease
23. Diagnosis and classification of optic neuritis
24. Infection in NMOSD: Analyzing the Patterns of Infection in the SAkura Studies, Satralizumab Post-marketing Data, and NMOSD US PharMetrics Claims Data (P10-14.003)
25. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
26. Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD
27. Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
28. Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life
29. Myelin-oligodendrocyte glycoprotein antibody-associated disease
30. Myelin oligodendrocyte glycoprotein antibody‐associated disorders: An overview
31. Eculizumab in AQP4+ neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance
32. Diagnostic considerations for MS across the world
33. International MOGAD criteria
34. Dynamic Changes in Patient Admission and Their Disabilities in Multiple sclerosis and Neuromyelitis Optica: A Japanese Nationwide Administrative Data Study
35. Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders
36. CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
37. New therapies for neuromyelitis optica spectrum disorder
38. Restoring immune tolerance in neuromyelitis optica
39. Restoring immune tolerance in neuromyelitis optica
40. Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody
41. Myelin oligodendrocyte glycoprotein antibody‐associated disorders: An overview.
42. White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments
43. Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD)
44. Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects
45. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide
46. Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy
47. GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder
48. Patterns of regional brain volume loss in multiple sclerosis: a cluster analysis
49. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
50. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.